Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study.
Esther Wei Yin ChangValerie Shiwen YangShin Yeu OngHilda Xueqi KangBoon Yee LimSanjay de MelEsther Ka Yan NgMichelle Limei PoonYa Hwee TanJianbang ChiangEileen PoonNagavalli SomasundaramMohamad FaridTiffany TangMiriam TaoLay Poh KhooChee Leong ChengDachuan HuangChoon Kiat OngSoon Thye LimJason Yongsheng ChanPublished in: Leukemia & lymphoma (2023)
In our Asian multicenter retrospective study, we investigated the clinical prognostic factors affecting the outcomes of AITL patients and identified a novel prognostic index relevant in the Asian context. In our 174-patient cohort, the median PFS and OS was 1.8 years and 5.6 years respectively. Age > 60, bone marrow involvement, total white cell count >12 × 10 9 /L and raised serum lactate dehydrogenase were associated with poorer PFS and OS in multivariate analyses. This allowed for a prognostic index (AITL-PI) differentiating patients into low (0-1 factors, n = 64), moderate (2 factors, n = 59) and high-risk (3-4 factors, n = 49) subgroups with 5-year OS of 84.0%, 44.0% and 28.0% respectively ( p < 0.0001). POD24 proved to be strongly prognostic (5-year OS 24% vs 89%, p < 0.0001). Exploratory gene expression studies were performed and disparate immune cell profiles and cell signaling signatures were seen in the low risk group as compared to the intermediate and high risk groups.
Keyphrases
- gene expression
- end stage renal disease
- bone marrow
- ejection fraction
- risk factors
- chronic kidney disease
- newly diagnosed
- single cell
- prognostic factors
- peritoneal dialysis
- type diabetes
- dna methylation
- magnetic resonance imaging
- stem cells
- cell therapy
- high intensity
- metabolic syndrome
- cross sectional
- contrast enhanced
- data analysis